

Human Recombinant Muscarinic Acetylcholine Receptor M1 Stable Cell Line**Cat. No. M00251****Version 05292014**

I	Introduction	1
II	Background.....	1
III	Representative Data.....	2
IV	Thawing and Subculturing.....	4
V	References	5
	Limited Use License Agreement.....	6

I. INTRODUCTION

Catalog Number: M00185

Cell Line Name: CHO-K1/M1

Gene Synonyms: M1; HM1; MGC30125; CHRM1

Expressed Gene: Genbank Accession Number NM_000738; no expressed tags

Host Cell: CHO-K1

Quantity: Two vials of frozen cells (3×10^6 per vial)

Stability: 16 passages

Application: Functional assay for M1 receptor

Freeze Medium: 45% culture medium, 45% FBS, and 10% DMSO

Complete Culture Medium: Ham's F12, 10% FBS

Culture Medium: Ham's F12, 10% FBS, 500 $\mu\text{g/ml}$ Penicillin-Streptomycin, 200 $\mu\text{g/ml}$ Zeocin

Mycoplasma Status: Negative

Storage: Liquid nitrogen upon receiving

II. BACKGROUND

M1 was expressed in the CNS such as cerebral cortex, basal ganglia, limbic areas, vestibular system and esophageal smooth muscle. Synaptic transmission by muscarinic acetylcholine receptors (mAChRs) is employed throughout the central and peripheral nervous systems to elicit a large and diverse array of neurophysiological actions. An important aspect of mAChR functional diversity is reflected by the multitude of biochemical and electrophysiological actions evoked by acetylcholine binding to mAChRs, which include the regulation of intracellular levels of cAMP, cGMP and inositol phospholipids, and the opening or closing of the potassium, calcium, and chloride ion channels found in certain tissues.

III. REPRESENTATIVE DATA

Concentration-dependent stimulation of intracellular calcium mobilization by Carbachol in CHO-K1/M1 and CHO-K1 cells




Figure 1. Carbachol-induced concentration-dependent stimulation of intracellular calcium mobilization in CHO-K1/M1 and CHO-K1 cells. The cells were loaded with Calcium-4 prior to stimulation with an M1 receptor agonist, carbachol. The intracellular calcium change was measured by FlexStation. The relative fluorescent units (RFU) were plotted against the log of the cumulative doses (10-fold dilution) of carbachol (Mean ± SD, n = 2). The EC₅₀ of carbachol on M1 in CHO-K1 cells was 0.44 nM. The S/B of carbachol on M1 in CHO-K1 cells was 76.




Figure 2. Oxotremorine-induced concentration-dependent stimulation of intracellular calcium mobilization in CHO-K1/M1 and CHO-K1 cells. The cells were loaded with Calcium-4 prior to stimulation with an M1 receptor agonist, oxotremorine. The intracellular calcium change was measured by FlexStation III. The relative fluorescent units (RFU) were plotted against the log of the cumulative doses (10-fold dilution) of oxotremorine I (Mean ± SD, n = 2). The EC₅₀ of

oxotremorine on M1 in CHO-K1 cells was 1.3nM. The S/B of oxotremorine on M1 in CHO-K1 cells was 15.5.




Figure 3. Pirenzepine-induced concentration-dependent inhibition of intracellular calcium mobilization in CHO-K1/M1 cells. The cells were loaded with Calcium-4 prior to inhibition with an M1 receptor antagonist, Pirenzepine then EC₈₀ of agnosit oxotremorine. The intracellular calcium change was measured by FlexStation III. The relative fluorescent units (RFU) were plotted against the log of the cumulative doses (10-fold dilution) of Pirenzepine (Mean ± SD, n = 2). The IC₅₀ of Pirenzepine on M1 in CHO-K1 cells was 192 nM.

Notes:

1. EC₅₀ value is calculated with four parameter logistic equation:

$$Y = \text{Bottom} + \frac{\text{Top} - \text{Bottom}}{1 + 10^{((\text{LogEC}_{50} - X) * \text{HillSlope})}}$$

X is the logarithm of concentration.
 Y is RFU and starts at Bottom and goes to Top with a sigmoid shape.
2. Signal to background Ratio (S/B) = Top/Bottom

IV. RADIOLIGAND BINDING ASSAY




Figure 4. 10 µg of membranes prepared from CHO-K1 cells stably expressing M1 receptors were incubated with indicated concentrations of [³H]-Methylscopolamine ([³H]NMS) in the absence (total binding) or presence of 1000-fold excess unlabeled Atropine (nonspecific binding, NSB). Binding was terminated by rapid filtration. Specific binding was defined by subtracting NSB from total binding. Data were fit to one-site binding equation using a non-linear regression method.




Figure 5. 10 µg of membranes prepared from CHO-K1 cells stably expressing M1 receptors were incubated with indicated concentrations of Atropine in the presence of 0.2 nM [³H]-Methylscopolamine ([³H]NMS). Binding was terminated by rapid filtration. Data were fit to one-site competition equation using a non-linear regression method.

V. THAWING AND SUBCULTURING

Thawing Protocol

1. Remove the vial from liquid nitrogen tank and thaw cells quickly in a 37°C water-bath.
2. Just before the cells are completely thawed, decontaminate the outside of the vial with 70% ethanol and transfer the cells to a 15 ml centrifuge tube containing 9 ml of complete growth medium.
3. Pellet cells by centrifugation at 200 x g force for 5 min, and remove the medium.
4. Resuspend the cells in complete growth medium.
5. Transfer the cell suspension to a 10 cm dish with 10 ml of complete growth medium.
6. Grow the cells in incubator with 37°C, 5 %CO₂.
7. In the following day, replace the cells with fresh medium contains antibiotic.

Sub-culturing Protocol

1. Remove the culture medium from cells.
2. Wash cells with PBS (pH=7.4) to remove all traces of serum that contains trypsin inhibitor.
3. Add 2.0 ml of 0.05% (w/v) Trypsin- EDTA (GIBCO, Cat No. 25300) solution into 10 cm dish and observe the cells under an inverted microscope until cell layer is dispersed (usually within 3 to 5 minutes).
Note: To avoid cells clumping, do not agitate the cells by hitting or shaking the dish while waiting for the cells detach. If cells are difficult to detach, please place the dish in 37°C incubator for ~2 min.
4. Add 6.0 to 8.0 ml of complete growth medium into dish and aspirate cells by gently pipetting.
5. Centrifuge the cells at 200 x g force for 5min, and remove the medium.
6. Resuspend the cells in culture medium and add the cells suspension to new culture dish.
7. Grow the cells in incubator with 37°C, 5 %CO₂.

Subcultivation Ratio: 1:3 to 1:8 weekly.

Medium Renewal: Every 2 to 3 days

VI. REFERENCES

1. Monica Lupu-Meiri (2001) Constitutive signaling by Kaposi's sarcoma-associated herpesvirus G-protein-coupled receptor desensitizes calcium mobilization by other receptors. *The Journal of Biological Chemistry*. Vol.276 No.10: 7122–7128.
2. Osamu Moro (1994) Overlapping multi-site domains of the muscarinic cholinergic Hm1 receptor involved in signal transduction and sequestration. *J. Biol. Chem.* Vol.269 No.9: 6651–6655
3. Lara M.Tolbert (1996) Human muscarinic cholinergic receptor Hm1 internalizes via clathrin-coated vesicles. *J. Biol. Chem.* Vol.271 No.29: 17335–17342
4. Petra Hogger (1995) Activating and inactivating mutations in N- and C-terminal i3 loop junctions of muscarinic acetylcholine Hm1 receptors. *J. Biol. Chem.* Vol.270. No.13: 7405–7410

GenScript USA Inc,
860 Centennial Ave.
Piscataway, NJ 08854
Toll-Free: 1-877-436-7274
Tel: 1-732-885-9188, Fax: 1-732-210-0262
Email: product@genscript.com
Web: <http://www.genscript.com>

For Research Use Only.

Limited Use License Agreement

This is a legal agreement between you (Licensee) and GenScript USA Inc. governing use of GenScript's stable cell line products and protocols provided to licensee. By purchasing and using the stable cell line, the buyer agrees to comply with the following terms and conditions of this label license and recognizes and agrees to such restrictions:

- 1) The products are not transferable and will be used at the site where they were purchased. Transfer to another site owned by buyer will be permitted only upon written request by buyer followed by subsequent written approval by GenScript.
- 2) The purchaser cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party.
- 3) The products sold by GenScript are for laboratory and animal research purposes only. The products are not to be used on humans, for consumption, or for any unlawful uses.

GenScript USA Inc. will not assert against the buyer a claim of infringement of patents owned or controlled by GenScript USA Inc. and claiming this product based upon the manufacture, use or sale of a clinical diagnostic, therapeutic and vaccine, or prophylactic product developed in research by the buyer in which this product or its components has been employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on the use of this product for other purposes, contact Marketing Department, GenScript USA Inc., 120 Centennial Avenue, Piscataway, New Jersey 08840, U.S.A. Phone: 1-732-885-9188. Fax: 1-732-210-0262. Email: marketing@genscript.com.

860 Centennial Ave., Piscataway, NJ 08854, USA

Toll-Free: 1-877-436-7274 Tel: 1-732-885-9188 Fax: 1-732-210-0262 Email: product@genscript.com Web: www.genscript.com